PhaseBio Pharmaceuticals, Inc. (PHAS)
R&D to Revenue
942.73%
Fiscal year · Period ending:
PHAS R&D to Revenue
Latest reported942.73%period ending
Latest reported942.73%period ending
PHAS FY R&D/Revenue (0.00% → 942.73%)
Latest values, visible window
High-resolution chart · PNG
PHAS r&d to revenue history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 942.7292% | |
| 22,527.5% | |
| 1,309.2334% | |
| 2,313.6228% | |
| 0% | |
| 0% |